# OnCo record cemiplimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cemiplimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cemiplimab" ;
  schema:name "Cemiplimab"@en ;
  schema:description "A PD-1 blocker that is the standard for advanced skin squamous cell carcinoma, and in 2025 became the first adjuvant immunotherapy for it."@en ;
  schema:url <https://onco.cc/drugs/cemiplimab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cemiplimab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q55606818> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cemiplimab>, <https://www.nice.org.uk/guidance/ta1165> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "Libtayo" ;
  onco:approval "US 2018: Advanced cutaneous squamous cell carcinoma", "US 2025: Adjuvant high-risk CSCC after surgery and radiation", "England (NICE) 2026: Untreated locally advanced non-small-cell lung cancer unsuitable for definitive chemoradiation, or metastatic disease, with PD-L1 in 1 percent or more of tumour cells and no EGFR or ALK alteration, with platinum-based chemotherapy" ;
  onco:acceleratedApproval "US 2021-02-09: Patients with metastatic basal cell carcinoma (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate" ;
  onco:acceleratedApprovalConfirmed "US 2023-04-28: Patients with metastatic basal cell carcinoma (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate" ;
  onco:related <https://onco.cc/biomarkers/pd-l1-tps/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/pdl1-high-nsclc/>, <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/advanced-cutaneous-scc/>, <https://onco.cc/cancers/lip-cancer/>, <https://onco.cc/cancers/basal-cell-carcinoma/>, <https://onco.cc/cancers/locally-advanced-bcc/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:terms <https://onco.cc/terms/skin-cancer-after-organ-transplant/> ;
  onco:trials <https://onco.cc/trials/nct06246916/>, <https://onco.cc/trials/nct05800015/>, <https://onco.cc/trials/nct06585410/>, <https://onco.cc/trials/nct05317858/>, <https://onco.cc/trials/nct05608291/>, <https://onco.cc/trials/nct05785767/>, <https://onco.cc/trials/nct03972657/>, <https://onco.cc/trials/nct04050436/>, <https://onco.cc/trials/nct06463665/>, <https://onco.cc/trials/nct05557591/>, <https://onco.cc/trials/nct04291105/>, <https://onco.cc/trials/nct06162572/>, <https://onco.cc/trials/nct06161441/>, <https://onco.cc/trials/nct03916627/>, <https://onco.cc/trials/nct06190951/>, <https://onco.cc/trials/nct07594106/>, <https://onco.cc/trials/nct06413680/>, <https://onco.cc/trials/nct06769698/>, <https://onco.cc/trials/nct04305795/>, <https://onco.cc/trials/nct06908304/>, <https://onco.cc/trials/nct06384807/>, <https://onco.cc/trials/nct04626635/>, <https://onco.cc/trials/nct05208944/>, <https://onco.cc/trials/nct03491683/>, <https://onco.cc/trials/empower-lung-1/>, <https://onco.cc/trials/c-post/>, <https://onco.cc/trials/neoadjuvant-cemiplimab-cscc/>, <https://onco.cc/trials/cemiplimab-advanced-bcc/>, <https://onco.cc/trials/cemiplimab-kidney-transplant-cscc/> .